Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 782,316
  • Shares Outstanding, K 266,094
  • Annual Sales, $ 1,700 K
  • Annual Income, $ -208,380 K
  • EBIT $ -186 M
  • EBITDA $ -180 M
  • 60-Month Beta 2.04
  • Price/Sales 445.06
  • Price/Cash Flow N/A
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 102.18% ( -8.70%)
  • Historical Volatility 88.49%
  • IV Percentile 38%
  • IV Rank 24.72%
  • IV High 371.14% on 04/30/24
  • IV Low 13.86% on 09/12/24
  • Put/Call Vol Ratio 1.90
  • Today's Volume 61
  • Volume Avg (30-Day) 329
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 7,537
  • Open Int (30-Day) 4,796

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.21
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.33
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +52.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.69 +9.29%
on 11/21/24
4.69 -37.31%
on 10/28/24
-1.50 (-33.78%)
since 10/22/24
3-Month
2.69 +9.29%
on 11/21/24
5.00 -41.20%
on 10/18/24
-1.02 (-25.76%)
since 08/22/24
52-Week
2.69 +9.29%
on 11/21/24
7.45 -60.54%
on 01/12/24
-1.54 (-34.38%)
since 11/22/23

Most Recent Stories

More News
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

AUTL : 2.94 (+3.52%)
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

AUTL : 2.94 (+3.52%)
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

AUTL : 2.94 (+3.52%)
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

AUTL : 2.94 (+3.52%)
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

AUTL : 2.94 (+3.52%)
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments

The Chart of the Day belongs to the oncology based biomedical company Autolus Therapeutics (AUTL) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

AUTL : 2.94 (+3.52%)
Why Autolus Therapeutics Stock Is Crashing Today

Shares of Autolus Therapeutics (NASDAQ: AUTL) were crashing 35.9% as of 10:34 a.m. ET on Friday. The steep decline came after the biopharmaceutical company announced the price of a public stock offering...

AUTL : 2.94 (+3.52%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
SNTI : 2.17 (+2.39%)
INBX : 14.08 (+0.72%)
IMVT : 26.87 (+1.24%)
AUTL : 2.94 (+3.52%)
BMY : 58.87 (+1.10%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 58.87 (+1.10%)
ONC.TO : 1.33 (-2.92%)
ONCY : 0.9541 (-2.64%)
SNTI : 2.17 (+2.39%)
INBX : 14.08 (+0.72%)
IMVT : 26.87 (+1.24%)
AUTL : 2.94 (+3.52%)
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call,...

AUTL : 2.94 (+3.52%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 3.36
2nd Resistance Point 3.21
1st Resistance Point 3.07
Last Price 2.94
1st Support Level 2.78
2nd Support Level 2.63
3rd Support Level 2.49

See More

52-Week High 7.45
Fibonacci 61.8% 5.63
Fibonacci 50% 5.07
Fibonacci 38.2% 4.51
Last Price 2.94
52-Week Low 2.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar